133 related articles for article (PubMed ID: 12884364)
1. Prostate-specific antitumor activity by probasin promoter-directed p202 expression.
Wen Y; Giri D; Yan DH; Spohn B; Zinner RG; Xia W; Thompson TC; Matusik RJ; Hung MC
Mol Carcinog; 2003 Jul; 37(3):130-7. PubMed ID: 12884364
[TBL] [Abstract][Full Text] [Related]
2. p202, an interferon-inducible protein, mediates multiple antitumor activities in human pancreatic cancer xenograft models.
Wen Y; Yan DH; Wang B; Spohn B; Ding Y; Shao R; Zou Y; Xie K; Hung MC
Cancer Res; 2001 Oct; 61(19):7142-7. PubMed ID: 11585747
[TBL] [Abstract][Full Text] [Related]
3. Proapoptotic and antitumor activities of adenovirus-mediated p202 gene transfer.
Ding Y; Wen Y; Spohn B; Wang L; Xia W; Kwong KY; Shao R; Li Z; Hortobagyi GN; Hung MC; Yan DH
Clin Cancer Res; 2002 Oct; 8(10):3290-7. PubMed ID: 12374701
[TBL] [Abstract][Full Text] [Related]
4. Use of the probasin promoter ARR2PB to express Bax in androgen receptor-positive prostate cancer cells.
Andriani F; Nan B; Yu J; Li X; Weigel NL; McPhaul MJ; Kasper S; Kagawa S; Fang B; Matusik RJ; Denner L; Marcelli M
J Natl Cancer Inst; 2001 Sep; 93(17):1314-24. PubMed ID: 11535706
[TBL] [Abstract][Full Text] [Related]
5. Retinoblastoma (Rb) protein upregulates expression of the Ifi202 gene encoding an interferon-inducible negative regulator of cell growth.
Xin H; Pramanik R; Choubey D
Oncogene; 2003 Jul; 22(31):4775-85. PubMed ID: 12894219
[TBL] [Abstract][Full Text] [Related]
6. Reduced growth rate and transformation phenotype of the prostate cancer cells by an interferon-inducible protein, p202.
Yan DH; Wen Y; Spohn B; Choubey D; Gutterman JU; Hung MC
Oncogene; 1999 Jan; 18(3):807-11. PubMed ID: 9989832
[TBL] [Abstract][Full Text] [Related]
7. p202, an interferon-inducible negative regulator of cell growth, is a target of the adenovirus E1A protein.
Xin H; D'Souza S; Fang L; Lengyel P; Choubey D
Oncogene; 2001 Oct; 20(47):6828-39. PubMed ID: 11687962
[TBL] [Abstract][Full Text] [Related]
8. A small composite probasin promoter confers high levels of prostate-specific gene expression through regulation by androgens and glucocorticoids in vitro and in vivo.
Zhang J; Thomas TZ; Kasper S; Matusik RJ
Endocrinology; 2000 Dec; 141(12):4698-710. PubMed ID: 11108285
[TBL] [Abstract][Full Text] [Related]
9. Retardation of cell proliferation after expression of p202 accompanies an increase in p21(WAF1/CIP1).
Gutterman JU; Choubey D
Cell Growth Differ; 1999 Feb; 10(2):93-100. PubMed ID: 10074903
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of E2F-4/DP-1-stimulated transcription by p202.
Choubey D; Gutterman JU
Oncogene; 1997 Jul; 15(3):291-301. PubMed ID: 9233764
[TBL] [Abstract][Full Text] [Related]
11. Cancer-specific gene therapy.
Lo HW; Day CP; Hung MC
Adv Genet; 2005; 54():235-55. PubMed ID: 16096014
[TBL] [Abstract][Full Text] [Related]
12. P202, an interferon-inducible protein, inhibits E2F1-mediated apoptosis in prostate cancer cells.
Yan DH; Abramian A; Li Z; Ding Y; Wen Y; Liu TJ; Hunt K
Biochem Biophys Res Commun; 2003 Mar; 303(1):219-22. PubMed ID: 12646190
[TBL] [Abstract][Full Text] [Related]
13. Constitutive expression of the interferon-inducible protein p202 in NIH 3T3 cells affects cell cycle progression.
Lembo D; Angeretti A; Benefazio S; Hertel L; Gariglio M; Novelli F; Landolfo S
J Biol Regul Homeost Agents; 1995; 9(2):42-6. PubMed ID: 9127631
[TBL] [Abstract][Full Text] [Related]
14. p202 prevents apoptosis in murine AKR-2B fibroblasts.
Koul D; Lapushin R; Xu HJ; Mills GB; Gutterman JU; Choubey D
Biochem Biophys Res Commun; 1998 Jun; 247(2):379-82. PubMed ID: 9642135
[TBL] [Abstract][Full Text] [Related]
15. Tumor suppression and sensitization to tumor necrosis factor alpha-induced apoptosis by an interferon-inducible protein, p202, in breast cancer cells.
Wen Y; Yan DH; Spohn B; Deng J; Lin SY; Hung MC
Cancer Res; 2000 Jan; 60(1):42-6. PubMed ID: 10646849
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of LNCaP prostate tumor growth in vivo by an antisense oligonucleotide directed against the human androgen receptor.
Eder IE; Hoffmann J; Rogatsch H; Schäfer G; Zopf D; Bartsch G; Klocker H
Cancer Gene Ther; 2002 Feb; 9(2):117-25. PubMed ID: 11857028
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of E2F-mediated transcription by p202.
Choubey D; Li SJ; Datta B; Gutterman JU; Lengyel P
EMBO J; 1996 Oct; 15(20):5668-78. PubMed ID: 8896460
[TBL] [Abstract][Full Text] [Related]
18. PC3, but not DU145, human prostate cancer cells retain the coregulators required for tumor suppressor ability of androgen receptor.
Litvinov IV; Antony L; Dalrymple SL; Becker R; Cheng L; Isaacs JT
Prostate; 2006 Sep; 66(12):1329-38. PubMed ID: 16835890
[TBL] [Abstract][Full Text] [Related]
19. Development of a prostate-specific promoter for gene therapy against androgen-independent prostate cancer.
Furuhata S; Ide H; Miura Y; Yoshida T; Aoki K
Mol Ther; 2003 Mar; 7(3):366-74. PubMed ID: 12668132
[TBL] [Abstract][Full Text] [Related]
20. Androgen receptor regulation of G1 cyclin and cyclin-dependent kinase function in the CWR22 human prostate cancer xenograft.
Gregory CW; Johnson RT; Presnell SC; Mohler JL; French FS
J Androl; 2001; 22(4):537-48. PubMed ID: 11451350
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
